ALB and breast carcinoma: The hydrophobic interaction between HSA in HTI-NPs and paclitaxel enables their combination, while the stable ion pair formation between TOS and doxorubicin provides favorable conditions for the co-administration of HTI-NPs with existing clinical breast cancer chemotherapeutic drugs (17, 57).